Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
– Additional monotherapy dose-escalation data from ongoing Phase 1/1b clinical trial of WTX-124 expected to be presented in the first […]
EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments
– Announced positive topline efficacy and safety data from the Phase 2 DAVIO 2 trial of EYP-1901 in wet AMD […]
Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD
CHARLESTOWN, Mass., March 07, 2024 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic […]
Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024
STAMFORD, Conn., March 07, 2024 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment […]
Helius Medical Technologies, Inc. to Present at the 36th Annual ROTH Conference
NEWTOWN, Pa., March 07, 2024 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company […]
Manitoba Harvest Hemp Foods Introduces Protein-Rich Breakfast Staples With New Superseed Instant Oatmeal
NEW YORK and WINNIPEG, Manitoba, March 07, 2024 (GLOBE NEWSWIRE) — Manitoba Harvest, a leader in hemp-based foods and a […]
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook
• Dose escalation in FHD-286 combination study in AML continues to progress; clinical data anticipated in the second half of […]
Astec Announces Chief Financial Officer Transition
CHATTANOOGA, Tenn., March 07, 2024 (GLOBE NEWSWIRE) — Astec Industries, Inc. (NASDAQ:ASTE) (“Astec” or the “Company”) today announced the appointment […]
Harvard Bioscience Announces Fourth Quarter 2023 Financial Results
Q4 Revenues of $28.2 million Q4 Gross Margin of 58.0% (230 bps year-over-year improvement) Q4 operating income of $0.3 million, […]
Cibus to Report Fourth Quarter 2023 Financial Results on March 21, 2024 and Host Conference Call
SAN DIEGO, March 07, 2024 (GLOBE NEWSWIRE) — Cibus, Inc. (Nasdaq: CBUS), a leading agricultural biotechnology company that uses proprietary […]
